Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis
Recruiting · NCT06161376 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Toulouse
View the official record on ClinicalTrials.gov →Interventions studied
S1P level
What this trial is about
This study aims to establish a link between urinary Sphingosine 1-Phosphate (S1P) levels and detrusor activity in multiple sclerosis (MS) patients. MS often involves urological symptoms, primarily overactive bladder. The gold standard for evaluation and treatment monitoring is invasive urodynamic testing. Preliminary research at Toulouse University Hospital suggests urinary S1P levels may be a potential biomarker for detrusor activity in MS. This study aims to confirm this potential biomarker's utility.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- French residents enrolled in the social security system
- Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not
- Patients scheduled for urodynamic assessment as part of their management
Exclusion criteria
- Pregnant or lactating females
- Patients under legal guardianship
- Untreated urinary tract infection at the time of inclusion
- Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty
Where it is running
1 location listed.
- Toulouse Hospital - Toulouse, France